Navigation Links
OncoSec to Present at 15th Annual Biotech and Specialty Pharmaceuticals Conference
Date:11/28/2011

SAN DIEGO, Nov. 28, 2011 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB: ONCS), a biotechnology company developing its advanced-stage OMS ElectroOncology therapies to treat skin cancer and other solid tumor cancers, today announced that Punit Dhillon, President and CEO, will be presenting at the 15th Annual Biotech and Specialty Pharmaceuticals Conference in New York City.

(Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

15th Annual Biotech and Specialty Pharmaceuticals Conference
NYSSA Conference Center
1540 Broadway
New York, New York 10036
November 30, 2011
3:00pm ET

A live and archived webcast will be accessible on OncoSec's website www.oncosec.com

The New York Society of Analysts will be holding their 15th annual Biotech and Specialty Pharmaceuticals Conference to open opportunities for investors to be introduced to innovative emerging small and micro-cap biotech companies. Companies are invited to give 30-minute presentations to present their research, discuss progress and investment outlook for new drugs, diagnostics and delivery technologies.

About OncoSec Medical Inc.

OncoSec Medical Incorporated (OTCBB: ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapies have achieved validating safety and efficacy data in early and late st
'/>"/>

SOURCE OncoSec Medical Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
2. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
3. OncoSec Medical to Present at ROTH 23rd Annual Growth Stock Conference
4. OncoSec Medical Closes $1.1M Financing
5. OncoSec Medical Closes Purchase and License Agreement for Tumor Therapy Technology with Inovio Pharmaceuticals
6. OncoSec Medical Announces the Appointment of Dr. Anthony E. Maida, III, to Its Board of Directors
7. OncoSec Medical Appoints Engineering Leader
8. OncoSec Medical to Present at Industry and Investor Conferences
9. OncoSec Medical to Attend 6th Annual Fire, Ice and Beyond: The Future of Ablation Therapies Conference
10. OncoSec Announces Positive Results from Head & Neck and Breast Cancer Trials
11. Update: OncoSec Announces Positive Results From Head & Neck and Breast Cancer Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , April 17, 2015 CVS Health ... conference call on Friday, May 1, 2015, at 8:30 ... first quarter financial results. An audio webcast ... the Investor Relations portion of the CVS Health website ... http://investors.cvshealth.com . This webcast will be archived and ...
(Date:4/17/2015)... 2015  Trovagene, Inc., (NASDAQ:  TROV) a developer ... data presented at the 2015 European Lung Cancer ... Monitoring ℠ (PCM) platform outperformed tissue biopsy ... T790M mutations in metastatic lung cancer patients. ... Mutation in Urinary Circulating Tumor DNA from Metastatic ...
(Date:4/17/2015)... NEW YORK , April 17, 2015  Over the ... expected to continue to grow, with ArcView predicting that 14 ... will legalize medical marijuana. The U.S. market for legal cannabis ... $1.5 billion in 2013. Analysts project the market could grow ... years, assuming more states soften their stance on marijuana. ...
Breaking Medicine Technology:Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 2Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 4Cannabiz Mobile Analyst Brief: Next Big Thing by Torus IR Issued by BrokerBank Securities, Inc. 2
... May 22 Shire plc (LSE: SHP, Nasdaq: ... results of a study showing that coadministration of the ADHD ... (PPI) Prilosec OTC(R) 40 mg (20 mg X 2), did ... concentration of d -amphetamine to be reached in the ...
... Calif., May 21 Telik, Inc. (Nasdaq: TELK ... study of canfosfamide (TELCYTA(R), TLK286) in combination with pegylated liposomal ... annual meeting of the American Society of Clinical Oncology (ASCO) ... in Orlando, FL.Details of the presentation are as follows:, ...
Cached Medicine Technology:New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 2New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 3New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 4New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 5New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 6New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 7New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 8
(Date:4/17/2015)... (PRWEB) April 17, 2015 With Dr. ... Care has spent the last four years providing ... performing procedures ranging from general cleanings to dental implants ... grand opening at their new office in North Charlotte. ... services as their Concord office, including denture fittings, cosmetic ...
(Date:4/17/2015)... released a new blog post explaining the dangers of sleeping ... rates . , Falling asleep at the wheel can ... impact on auto insurance prices. The premiums will go up ... newly released blog post talks more about drowsiness at the ... is now possible to find low cost car insurance plans ...
(Date:4/17/2015)... Mario Badescu Botanical Exfoliating ... facial skin with its unique combination of finely ... energizing botanicals. This cushiony gel-based formula sloughs off ... and inhibit penetration of special treatments, serums, and ... Seeds, This uncommon exfoliating ingredient is an ecologically ...
(Date:4/17/2015)... Wholelifelifeinsurance.org has released a new ... life insurance policies . , Whole life insurance ... for their families at the same time. Whole life ... can be customized to it the client’s needs. ... clients take some appropriate steps.Comparing life insurance quotes is ...
(Date:4/17/2015)... 17, 2015 Verndale, a Global Experience ... once again been chosen as a Boston Business Journal ... company in the region. The BBJ’s Pacesetters represents privately ... 2011 through 2014. This is the eighth consecutive year ... that Verndale has been honored with this award. , ...
Breaking Medicine News(10 mins):Health News:Accidents Caused By Sleeping at The Wheel Can Increase Auto Insurance Costs 2Health News:Mario Badescu Skin Care Launches Botanical Exfoliating Scrub 2Health News:Whole Life Insurance Policies At Affordable Prices By Comparing Quotes 2Health News:Verndale Honored as 2015 Boston Business Journal Pacesetter, Named 46th Fastest Growing Private Company 2
... New research is challenging the notion that parents who ... the period following divorce. A large, longitudinal study conducted ... found that divorce does not change parenting behavior, and ... parenting between recently divorced and married parents. , The ...
... Script, Inc. today announced,that its mail order facility, ... Boards of Pharmacy (NABP) through its Verified,Internet Pharmacy ... must comply with the licensing and inspection,requirements of ... of each state to which,it dispenses medications. In ...
... Dental Work Improves Speech, Health As Well as Looks, ... had,an overbite so large he could put the tip of ... about it., Soraino, a former Army paratrooper and ski ... cosmetic,dentistry, to have his smile reconstructed., "I could put ...
... cell disease and who experience silent strokes showed some relief ... Washington University School of Medicine in St. Louis have found. ... of Pediatric Blood and Cancer but are available for review ... study of 10 children with sickle cell disease who also ...
... aims to solve why some people feel the constant need ... six adults - has received a prestigious new 420,000 award ... , Researchers from the UK and the Netherlands have teamed ... that was started in Newcastle upon Tyne and Maastricht by ...
... Sage, TAMPA, Fla., Dec. 10 Pediatric practices ... have recently selected Intergy EHR,by Sage as their Electronic ... the solution set provides essential,benefits especially geared toward a ... EHR by Sage as their,Electronic Health Records system include:, ...
Cached Medicine News:Health News:Massive study finds parenting practices don't suffer during divorce 2Health News:US Script Announces RxDirect VIPPS Accreditation 2Health News:A Better Smile Can Revive at Any Age 2Health News:Children with sickle cell disease, silent strokes show some relief with blood transfusions 2Health News:Children with sickle cell disease, silent strokes show some relief with blood transfusions 3Health News:International team gets new award to research the causes of bladder problems 2Health News:Pediatric Practices Select Intergy EHR by Sage for Electronic Health Records 2Health News:Pediatric Practices Select Intergy EHR by Sage for Electronic Health Records 3Health News:Pediatric Practices Select Intergy EHR by Sage for Electronic Health Records 4
... catheter or instrument introduction. The dual ... peeled away and removed. The maximum ... to be introduced should be measured ... sheath. Supplied sterile in peel-open packages. ...
... Used percutaneously to direct a ... wire guide to a specific ... has an inner stainless steel ... to the catheter shaft. Supplied ...
Used when establishing a percutaneous tract for nephrostomy drainage. The guide has a stiff shaft and a gradual transition to a very flexible distal tip. Supplied sterile in peel-open packages. Inten...
Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: